The Journal of Informed Pharmacotherapy 2004;15:150.
Reviewer: James McCormack, B.Sc. (Pharm), Pharm. D.
Reviewer's email address: firstname.lastname@example.org
Reviewer's profession/specialty: Associate Editor, Journal of Informed Pharmacotherapy
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD; Investigators in the WIZARD Study. JAMA 2003;290:1459-66 PubMed Citation
These investigators compared a 12-week course of azithromycin to placebo in patients with stable coronary artery disease.
7747 patients with a history of myocardial infarction and a C pneumoniae IgG titer of 1:16 or more. Fifty-one percent had angina and 17% were smokers. Post-MI therapy prior to study enrollment included aspirin (87%), ACE inhibitors (42%), beta-blockers (60%), and statins (60%). The average age of the patients was 62 years and 18% were female.
Patients were randomized in a blinded fashion to receive either azithromycin (600 mg PO daily for three days then weekly) or placebo for 12 weeks.
The median study duration follow-up was 14 months.
There was no difference between groups in the primary end point or any of its components; death, recurrent MI, revascularizations, or hospitalizations for angina. Azithromycin did produce a 9% absolute increase in the chance of diarrhea.
This study suggests that in patients with stable coronary artery disease, a 12 week course of azithromycin did not have an impact on coronary heart disease-related events.
Copyright © 2004 by the Journal of Informed Pharmacotherapy. All rights reserved.